Technical Analysis for RNAC - Cartesian Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 24.27 | -10.14% | -2.74 |
RNAC closed down 10.14 percent on Monday, July 1, 2024, on 46 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| Fell Below 200 DMA | Bearish | 0.00% | |
| Fell Below 50 DMA | Bearish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Spinning Top | Other | -10.14% | |
| Volume Surge | Other | -10.14% | |
| Inside Day | Range Contraction | -10.14% | |
| Wide Bands | Range Expansion | -10.14% | |
| 20 DMA Resistance | Bearish | -14.90% | |
| Crossed Above 200 DMA | Bullish | -14.90% |
| Alert | Time |
|---|---|
| 50 DMA Support | about 6 hours ago |
| 200 DMA Support | about 8 hours ago |
| Down 5% | about 8 hours ago |
| Fell Below 200 DMA | about 8 hours ago |
| Fell Below 50 DMA | about 8 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 08/15/2024
Cartesian Therapeutics is a clinical-stage company pioneering RNA cell therapies for the treatment of autoimmune diseases. The company’s lead asset, Descartes-08, is a potential first-in-class, RNA-engineered chimeric antigen receptor T-cell therapy (rCAR-T) in Phase 2b clinical development for patients with generalized myasthenia gravis, with additional Phase 2 studies planned in systemic lupus erythematosus as well as ocular autoimmune and vasculitic autoimmune basket trials. Cartesian operates a wholly owned, state-of-the-art cGMP manufacturing facility in Gaithersburg, MD.
Sector: Healthcare
Industry: Biotechnology
Keywords: Autoimmune Disease Cell Therapy Autoimmunity Lupus Myasthenia Gravis Sjögren Syndrome Systemic Lupus Erythematosus Therapies For The Treatment Of Autoimmune Diseases
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Autoimmune Disease Cell Therapy Autoimmunity Lupus Myasthenia Gravis Sjögren Syndrome Systemic Lupus Erythematosus Therapies For The Treatment Of Autoimmune Diseases
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 42.6 |
| 52 Week Low | 11.665 |
| Average Volume | 104,694 |
| 200-Day Moving Average | 25.48 |
| 50-Day Moving Average | 25.95 |
| 20-Day Moving Average | 28.57 |
| 10-Day Moving Average | 24.24 |
| Average True Range | 3.41 |
| RSI (14) | 44.44 |
| ADX | 25.73 |
| +DI | 22.95 |
| -DI | 18.98 |
| Chandelier Exit (Long, 3 ATRs) | 31.65 |
| Chandelier Exit (Short, 3 ATRs) | 31.46 |
| Upper Bollinger Bands | 38.76 |
| Lower Bollinger Band | 18.38 |
| Percent B (%b) | 0.29 |
| BandWidth | 71.31 |
| MACD Line | -0.65 |
| MACD Signal Line | -0.23 |
| MACD Histogram | -0.4138 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 31.12 | ||||
| Resistance 3 (R3) | 31.88 | 30.36 | 29.98 | ||
| Resistance 2 (R2) | 30.36 | 28.61 | 29.98 | 29.60 | |
| Resistance 1 (R1) | 27.31 | 27.53 | 26.55 | 26.55 | 29.22 |
| Pivot Point | 25.79 | 25.79 | 25.40 | 25.41 | 25.79 |
| Support 1 (S1) | 22.74 | 24.04 | 21.98 | 21.99 | 19.32 |
| Support 2 (S2) | 21.22 | 22.96 | 20.84 | 18.94 | |
| Support 3 (S3) | 18.17 | 21.22 | 18.56 | ||
| Support 4 (S4) | 17.42 |
